Business Description
NervGen Pharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA64082X2032
Share Class Description:
TSXV:NGEN: Ordinary SharesCompare
Compare
Traded in other countries / regions
NGEN.CanadaNGENF.USA9UA.Germany IPO Date
2019-03-13Description
NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for treating nerve damage and neurodegenerative diseases. NervGen is testing a new drug called NVG-291 in a Phase 1b/2a clinical trial. The company is developing drugs for treating spinal cord injury, multiple sclerosis, and Alzheimer's disease.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.89 | |||||
| Equity-to-Asset | -0.15 | |||||
| Debt-to-Equity | -0.1 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.6 | |||||
| 3-Year EPS without NRI Growth Rate | 5.8 | |||||
| 3-Year FCF Growth Rate | 0.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.64 | |||||
| 9-Day RSI | 43.74 | |||||
| 14-Day RSI | 41.71 | |||||
| 6-1 Month Momentum % | 13.4 | |||||
| 12-1 Month Momentum % | 39.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.83 | |||||
| Quick Ratio | 0.83 | |||||
| Cash Ratio | 0.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 | |||||
| Shareholder Yield % | 0.05 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -329.18 | |||||
| ROA % | -124.37 | |||||
| ROIC % | -201.06 | |||||
| ROC (Joel Greenblatt) % | -9075.36 | |||||
| ROCE % | -322.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -5.92 | |||||
| EV-to-EBITDA | -5.96 | |||||
| EV-to-FCF | -12.05 | |||||
| Earnings Yield (Greenblatt) % | -16.88 | |||||
| FCF Yield % | -7.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NervGen Pharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.38 | ||
| Beta | 0.65 | ||
| Volatility % | 75.24 | ||
| 14-Day RSI | 41.71 | ||
| 14-Day ATR (C$) | 0.155774 | ||
| 20-Day SMA (C$) | 2.1315 | ||
| 12-1 Month Momentum % | 39.24 | ||
| 52-Week Range (C$) | 1.5 - 3.98 | ||
| Shares Outstanding (Mil) | 69.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NervGen Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NervGen Pharma Corp Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
NervGen Pharma Corp Frequently Asked Questions
What is NervGen Pharma Corp(TSXV:NGEN)'s stock price today?
The current price of TSXV:NGEN is C$2.06. The 52 week high of TSXV:NGEN is C$3.98 and 52 week low is C$1.50.
When is next earnings date of NervGen Pharma Corp(TSXV:NGEN)?
The next earnings date of NervGen Pharma Corp(TSXV:NGEN) is .
Does NervGen Pharma Corp(TSXV:NGEN) pay dividends? If so, how much?
NervGen Pharma Corp(TSXV:NGEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers